LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Condition: Lung Cancer; Non-Small Cell Lung Cancer; Adenocarcinoma of Lung
MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Adenocarcinoma of Lung
Intervention: LMB-100; pembrolizumab; Mesothelin Expression; TrueSight Oncology 500
Intervention description: Participants will receive LMB-100 on days 1, 3 and 5 of a 21-day cycle for up to 2 cycles.; Participants will receive pembrolizumab on day 1 of each subsequent 21-day cycle.; Testing for mesothelin expression performed at screening; Testing for ROS oncogene 1 (ROS1) gene, anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) variations performed at screening.
Intervention MeSH terms: Pembrolizumab; LMB-100
Phase: Phase 2
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 6.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Immunotherapy; Checkpoint Inhibitor; Monoclonal Antibody; Lung Adenocarcinoma

Summary:

      Background:

      Over 230,000 new lung cancer cases are diagnosed every year in the United States (U.S.) About
      80% of lung cancers are non- small cell lung cancer (NSCLC). Most people have a more advanced
      stage of the disease that doesn't respond well to standard treatment. Researchers want to see
      if a combination of drugs may be able to help.

      Objective:

      To find out if LMB-100 followed by pembrolizumab can help tumors to shrink in people with
      NSCLC.

      Eligibility:

      People ages 18 and older with NSCLC that has not responded to standard therapies

      Design:

      Participants will be screened with:

        -  Medical history

        -  Physical exam

        -  Tumor sample. If one is not available, they will have a biopsy.

        -  Assessments of ability to perform normal activities

        -  Lung function tests

        -  Blood, heart, and urine tests

        -  Computed tomography (CT) and positron emission tomography (PET). They will lie in a
           machine that takes pictures of the body.

      Participants will take LMB-100 in 21-day cycles for up to 2 cycles. They will take the drug
      by injection into an arm vein on days 1, 3, and 5 of each cycle. They will stay in the
      hospital 7-10 days each cycle. Then they will get pembrolizumab by injection into an arm vein
      every 3 weeks for up to 2 years. They may be able to take pembrolizumab an additional year if
      their cancer gets worse.

      Participants will have repeats of the screening tests throughout the study.

      About 30 days and 90 days after they stop treatment, participants will have follow-up visits.
      Then they will have visits every 6-12 weeks. They will be followed for the rest of their life
      through phone calls and emails.
    

Eligibility criteria:

        -  INCLUSION CRITERIA:

        Participants are eligible to be included in the study only if all of the following criteria
        apply.

          -  Male and female participants who are at least 18 years of age on the day of signing
             the informed consent will be enrolled in the study.

          -  Subjects must have histologically confirmed diagnosis of non-squamous non-small cell
             lung cancer not amenable to potentially curative treatments (surgical resection,
             definitive radiation therapy or a combined modality approach) or targeted agents to
             actionable epidermal growth factor receptor (EGFR) mutations or Anaplastic lymphoma
             kinase (ALK) or ROS oncogene 1 (ROS1) gene rearrangement and excluding neuroendocrine
             tumors. Activating Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are
             allowed. The diagnosis must be confirmed by the Laboratory of Pathology, Center for
             Cancer Research (CCR), National Cancer Institute (NCI). Mutation confirmation may be
             done by referring institutions or by one of the assays in the Protocol.

          -  Have provided archival tumor tissue sample or newly obtained fresh core or excisional
             biopsy of a tumor lesion not previously irradiated. Formalin-fixed, paraffin embedded
             (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to
             archived tissue.

          -  Histologically confirmed 25% of tumor cells expressing mesothelin as determined by NCI
             Laboratory of Pathology. Determination can be made using archival tumor tissue or
             fresh biopsy.

          -  Have measurable disease based on Response Evaluation Criteria in Solid Tumors
             (RECIST). Lesions in a previously irradiated area are considered measurable if
             progression has been demonstrated in such lesions.

          -  Subjects must have received prior standard of care treatments for locally advanced or
             metastatic non-small cell lung cancer (NSCLC).

          -  Patients must be more than 3 weeks out of systemic treatments, such as chemotherapy.

          -  All acute toxic effects of any prior radiotherapy, chemotherapy, immunotherapy, or
             surgical procedure must have resolved to Grade less than or equal to 1, except
             alopecia (any grade) and Grade 2 peripheral neuropathy.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

          -  Evaluation of ECOG is to be performed within 7 days prior to start of study therapy.

          -  Have adequate organ and marrow function as defined below:

          -  Patients must have normal organ and marrow function as defined below:

               -  hemoglobin greater than or equal to 9g/dL or 5.6 mmol/L

               -  absolute neutrophil count greater than or equal to 1,500mcL

               -  platelets greater than or equal to 100,000/mcL

               -  total bilirubin less than or equal to 2.5 x the upper limit of normal range (UNL)
                  OR direct bilirubin less than or equal to ULN for participants with total
                  bilirubin levels of greater than 1.5 X ULN

               -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or
                  equal to 2.5 x ULN OR less than or equal to 5 x ULN for subjects with metastatic
                  disease to the liver

               -  creatinine greater than or equal to 1.5 x ULN OR creatinine clearance greater
                  than or equal to 50 mL/min for participants with creatinine levels greater than
                  1.5 X ULN

               -  International normalized ratio (INR) or prothrombin time (PT) or activated
                  thromboplastin time (aPTT) greater than or equal to 1.5 X ULN unless participant
                  is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic
                  range of intended use of anticoagulants

          -  Must have left ventricular ejection fraction >50%.

          -  The effects of LMB-100 on the developing human fetus are unknown. For this reason and
             because anti-PD-1 antibodies such as pembrolizumab are assumed to be teratogenic:

               -  A male participant must agree to use contraception during the treatment period
                  and for at least 180 days after the last dose of study treatment and refrain from
                  donating sperm

               -  A female participant is eligible to participate if she is not pregnant, not
                  breastfeeding, and at least one of the following conditions applies:

                    -  Not a woman of childbearing potential (WOCBP) OR

                    -  A WOCBP who agrees to follow the contraceptive guidance during the treatment
                       period and for at least 180 days after the last dose of study treatment.

               -  Should a woman become pregnant or suspect she is pregnant while she or her
                  partner is participating in this study, she should inform her treating physician
                  immediately.

               -  Ability of subject to understand and the willingness to sign a written informed
                  consent document.

               -  Subjects with non-life-threatening immune-related endocrinopathies or adverse
                  events (AEs) reduced to Grade 1 or 0 after withholding immune checkpoint
                  inhibitors (ICI) or medical intervention are eligible as long as the AE resolved
                  within 12 weeks of last dose and not requiring corticosteroids.

        EXCULSION CRITERIA:

          -  Is currently participating in or has participated in a study of an investigational
             agent or has used an investigational device within 4 weeks prior to the first dose of
             study treatment. Note: Participants who have entered the follow-up phase of an
             investigational study may participate as long as it has been 4 weeks after the last
             dose of the previous investigational agent.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis. Participants with previously treated brain metastases may participate
             provided they are radiologically stable, i.e., without evidence of progression for at
             least 4 weeks by repeat imaging (note that the repeat imaging should be performed
             during study screening), clinically stable and without requirement of steroid
             treatment for at least 14 days prior to first dose of study treatment.

          -  Subjects who have received prior therapy with LMB-100.

        Has received prior systemic anti-cancer therapy including investigational agents within 4
        weeks prior to start of study therapy.

          -  Note: Participants must have recovered from all AEs due to previous therapies to
             <=Grade 1 or baseline. Participants with <=Grade 2 neuropathy may be eligible.

          -  Note: If participant received major surgery, they must have recovered adequately from
             the toxicity and/or complications from the intervention prior to starting study
             treatment.

               -  Has received prior radiotherapy within 2 weeks of start of study treatment.
                  Participants must have recovered from all radiation-related toxicities, not
                  require corticosteroids, and not have had radiation pneumonitis. A 2-week washout
                  is permitted for palliative radiation (<=2 weeks of radiotherapy) to non-CNS
                  disease.

               -  Has received a live vaccine within 30 days prior to the first dose of study drug.
                  Examples of live vaccines include, but are not limited to, the following:
                  measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies,
                  Bacillus Calmette (BCG), and typhoid vaccine. Seasonal influenza vaccines for
                  injection are generally killed virus vaccines and are allowed; however,
                  intranasal influenza vaccines (e.g., FluMist(R)) are live attenuated vaccines and
                  are not allowed.

               -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid
                  therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other
                  form of immunosuppressive therapy within 7 days prior to start of study therapy.

               -  Has active autoimmune disease that has required systemic treatment in the past 2
                  years (i.e., with use of disease modifying agents, corticosteroids or
                  immunosuppressive drugs). Replacement therapy (e.g.., thyroxine, insulin, or
                  physiologic corticosteroid replacement therapy for adrenal or pituitary
                  insufficiency, etc.) is not considered a form of systemic treatment.

               -  Has a history of (non-infectious) pneumonitis/interstitial lung disease (ILD)
                  that required steroids or has current pneumonitis/ILD

               -  Has a history or current evidence of any condition, therapy, or laboratory
                  abnormality that might confound the results of the study, interfere with the
                  subject's participation for the full duration of the study, or is not in the best
                  interest of the subject to participate, in the opinion of the treating
                  investigator.

               -  Has known psychiatric or substance abuse disorders that would interfere with
                  cooperation with the requirements of the trial.

               -  A WOCBP who has a positive urine pregnancy test within 72 hours prior to start of
                  study therapy. If the urine test is positive or cannot be confirmed as negative,
                  a serum pregnancy test will be required. Note: In the event that 72 hours have
                  elapsed between the screening pregnancy test and the first dose of study
                  treatment, another pregnancy test (urine or serum) must be performed and must be
                  negative in order for subject to start receiving study medication.

               -  Is pregnant or breastfeeding or expecting to conceive or father children within
                  the projected duration of the study, starting with the screening visit through
                  180 days after the last dose of trial treatment. Pregnant women are excluded from
                  this study because LMB-100 + pembrolizumab are agents with the potential for
                  teratogenic or abortifacient effects. Because there is an unknown but potential
                  risk for adverse events in nursing infants secondary to treatment of the mother
                  with LMB-100 + pembrolizumab, breastfeeding should be discontinued if the mother
                  is treated with LMB-100 + pembrolizumab. These potential risks may also apply to
                  other agents used in this study.

               -  Has a known history of Human Immunodeficiency Virus (HIV). HIV positive patients
                  will be excluded due to a theoretical concern that the degree of immune
                  suppression associated with the treatment may result in progression of HIV
                  infection. (Note: No HIV testing is required)

               -  Has a known history of Hepatitis B (defined as Hepatitis B surface antigen
                  [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV ribonucleic
                  acid (RNA [qualitative] is detected) infection. or active hepatitis B virus (HBV)
                  or HCV infection. (Note: No testing for Hepatitis B and Hepatitis C is required.)

               -  Has a known additional malignancy that is progressing or has required active
                  treatment within the past 2 years. Note: Participants with basal cell carcinoma
                  of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g.,
                  breast carcinoma, cervical cancer in situ) that have undergone potentially
                  curative therapy are not excluded.

               -  Has an active infection requiring systemic therapy.

               -  Participants with contra-indication and/or history of severe hypersensitivity
                  reactions to any components related to LMB-100 or pembrolizumab (or any other
                  immune checkpoint inhibitor such as Programmed death ligand 1 (PD-1), programmed
                  death-ligand 1 (PD-L1) and cluster of differentiation 152 (CTLA-4).

               -  Active or uncontrolled infections.

               -  Subjects who experienced severe or life-threatening immune-related AEs with prior
                  immune checkpoint therapy requiring medical intervention (steroid or
                  immunosuppressant drugs) and permanent discontinuation of therapy, will be
                  excluded. These include, but not limited to colitis, autoimmune hepatitis,
                  hypophysitis, hyperthyroidism, nephritis, myocarditis, Guillain-Barré syndrome
                  (GBS), encephalitis.

               -  Subjects with a history of pneumonitis that required steroids will be excluded.

               -  Recruitment Strategies

        Information about the study will be posted on sites such as clinicaltrials.gov and the
        Center for Cancer Research (CCR) recruitment website. Subjects will also be drawn from
        patients seen at the thoracic clinic at the National Institutes of Health (NIH) Clinical
        Center as well as from referrals from outside providers. Social media platforms managed by
        NIH/National Cancer Institute (NCI) may also be used to publicize the study. There is no
        plan to advertise this study at this time.